A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)

Trial Profile

A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Capecitabine; Docetaxel; Gemcitabine
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Acronyms Keynote-122
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Aug 2017 Planned number of patients changed from 160 to 230.
    • 28 Aug 2017 Planned End Date changed from 14 Aug 2019 to 5 Mar 2020.
    • 28 Aug 2017 Planned primary completion date changed from 21 Jan 2019 to 5 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top